CD19 and neoplasm: BiAbs targeting CD47xCD19 or CD47xMSLN were tested in immunodeficient mice implanted with the following human tumor cell lines: Raji (CD19+, lymphoma), OVCAR-3 (MSLN+, ovarian) or MSLN-transfected HepG2 (hepatic).